valid the testing was, how well the testing was done. Here you are, you have phase three results, samples that, in my opinion, could confirm those and therefore remove the controversy. What I have as an opinion is still somewhat to investors who have not gone into the stock because that created a lot. You know, if you remember, if you look back three years ago, the stock was approaching $100, and because of those controversies, the stock got whacked significantly because there was just really a lot of doubt as far as those results, yet the company was going into phase three. In my opinion, the phase three results will confirm that the drug works the way it's supposed to, and that is going to be confirmed by positive biomarker results.
He won't say it, but I'll say it because that's part of my job.
But we're gonna do more than that. We're gonna do more than that because this, you know, I'm well aware of the controversy of the company, believe me, and I've got a job to do, and that is to change the perception of this company, which I think we can do. Because, you know, when I went into the company in July as the Executive Chair, I didn't expect to remain as CEO. But seeing 30 people that are so unbelievably dedicated, and so professional, and so driven to bring a drug to Alzheimer's patients, it was incredible. And so when I look at the perception of, you know, things I read in Wall Street and things I see in Austin, Texas, it's 180 degrees.
So the way that we have to do it is we have to come up with more data, and what we're doing now is we're doing a number of experiments to verify our method of action. There's a series of them. We're doing them with independent labs, real labs, commercial labs around the world. I'm not gonna tell you what experiments, I'm not gonna tell you which labs, 'cause people will start calling them. But we'll have that data after the phase three. We will report that data, whether it is good, bad, or indifferent. And the other thing we're gonna do is, when we did our phase two study in the statistical analysis plan with FDA, we told them that we were gonna do an analysis of the plasma samples. It was never done.
For whatever reason, never done. We have 2,000 samples. Some of these are four years old. I can't be sure of the stability of the material, although we think it's stable. But we told the FDA we're gonna do it, so we are gonna do it, and we're just starting it now. We're gonna do an analysis of the plasma biomarkers from phase two. And, you know, again, I don't know how phase three is gonna come out. I don't know how that data's gonna come out. But imagine if we had a successful phase three, and then we had the backup of validated experiments, and then biomarkers from 2,000 samples in the phase two. That's a mountain of data. I mean, at that point, I think, you know, investors and hopefully the FDA will believe.
Again, all hypothetical. I don't know how the studies are gonna come out, but that's what we're doing.
Terrific. Well, I wanna thank Rick Barry, CEO, new CEO of Cassava Sciences, for joining us today and providing his insights. I think, hopefully, I see, you see what I see, which is I think, they've hired a good person to helm, the company to, the end of the phase three clinical trials. Thank you, and thank you for everyone for attending.
Thank you very much, Rune.
You're welcome.
Nice job.